OMO-103 is under clinical development by Peptomyc and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase I drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the OMO-103 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OMO-103 overview

OMO-103 is under development for the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) and metastatic pancreatic cancer. The therapeutic candidate is a cell penetrating peptide (CPP) and administered through intravenous route. It acts by targeting Myc proto-oncogene protein.

It was under development for treatment of solid tumors including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), sarcoma, salivary gland cancer, pancreatic cancer and colorectal cancer (CRC).

Peptomyc overview

Peptomyc is a drug development company focusing on the development of cell-penetrating peptides targeting the Myc oncoprotein for cancer treatment. The company develops Omomyc peptide targeting the Myc oncoprotein into clinically viable therapeutics for the treatment of human cancers. It uses Peptomyc technology and IP for the development of Myc inhibitor. Peptomyc’s Omomyc peptide displays cell penetrating properties and can enter cells and exert a strong anti-Myc activity that results in arrest or death of cancer cell lines. The company partners with research institutions and financial consulting firms. Peptomyc is headquartered in Barcelona, Spain.

For a complete picture of OMO-103’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.